Luke Halpern, Associate Editor

If Heidi Overton is confirmed, the FDA nominee's views on abortion pills, vaccines, and drug review could reshape pharmacists' daily work.

Andrew Bzowyckyj, PharmD, explains how pharmacists can use albuminuria, ejection fraction, and inflammation to drive earlier CKM risk stratification and patient care.

A diabetologist who lives with type 1 diabetes weighs in on real-time ketone monitoring and what it means for at-risk patients.

Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.

New data show Opill reaches uninsured, rural, and younger patients—putting pharmacists at the center of daily dosing counseling.

Older triglyceride drugs manage only 10% to 30% reductions; newer injectables go far further, with FCS as their first key role.

Stacey Cutrell, PharmD, BCACP, CDCES, on the PREVENT calculator, screening for secondary causes, intensive BP targets, and fixing stubborn blood pressure.

Abbott's Libre Duo 10 Day tracks both glucose and ketones to flag rising DKA risk in people with diabetes 2 years and older.

The first single-biomarker blood test is cleared for both rule-in and rule-out of amyloid pathology in primary and specialty care.

Nipocalimab is the first therapy approved specifically for wAIHA, a rare, life-threatening autoantibody disease driving red blood cell destruction.

Tracking 3-year changes in the heart stress marker separated older adults whose risk climbed from those whose risk resolved.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists can spot metabolic dysfunction-associated steatotic liver disease (MASLD) risk, weigh GLP-1 and MASH therapies, and pair medication with lifestyle change.

Novo Nordisk's false-advertising case against Eli Lilly turns on GLP-1 dosing—here's the context pharmacists need when patients ask which drug is better.

Before escalating therapy, Stacey M. Cutrell, PharmD, urges pharmacists to rule out pseudo-resistance and nonadherence driving stubborn blood pressure.

Cardiomyopathy, hepatitis B, breast cancer, hypertension, and myeloma decisions land in the FDA's final-quarter queue.

Finerenone, SGLT2s, and GLP-1s each target a different driver of CKD—pharmacists can tie every drug to a matching lifestyle change for adherence.

Jeremy Johnson, PharmD, on how oral and injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are helping high-risk patients hit LDL targets statins alone can't reach.

Genglycos wins accelerated approval to cut daily cornstarch reliance in patients aged 8 and older with the rare metabolic disorder.

Garetosmab-grts cut new heterotopic ossification lesions by 90% or more at 56 weeks in the phase 3 OPTIMA trial.

New data link T2DM and prediabetes to more numerous, more severe symptoms, especially postmenopause.

Framing systemic inflammation as a “slow burn” helps patients see why SGLT2 inhibitors and GLP-1s work across diabetes, heart failure, and CKD.

New ACC statement urges pharmacists to weigh cognition and frailty in every older adult's cardiovascular regimen.

Chronic kidney disease (CKD) in diabetes is often caught late. Standardized eGFR and UACR screening plus thoughtful sequencing can slow progression and cut CV risk.

Adding family-based behavioral treatment to standard care nearly doubled clinically meaningful weight loss in kids in the TEAM UP trial.

From dietitian referrals to setting realistic weight-loss expectations, Cornell maps the pharmacist's place on the MASLD team.

UNC Health's Stacey Cutrell breaks down the PREVENT calculator, secondary-cause screening, and special-population guidance for pharmacists.

From patient selection to prior authorization: Tim Pflederer, MD, on delivering guideline-directed CKD care beyond the 15-minute visit.

Modeling in Canada suggests price drops of up to 70% could make dual glucagon-like peptide-1 (GLP-1) RA/SGLT2 inhibitor therapy the preferred strategy for high-risk patients with type 2 diabetes (T2D).

Andrew Bzowyckyj, PharmD, explains how the CKM framework turns albuminuria, ejection fraction, and inflammation into patient-specific risk stratification.

From double-dipping GLP-1s to off-label pioglitazone, Susan Cornell, PharmD, breaks down where the metabolic dysfunction-associated steatotic liver disease (MASLD) drug evidence stands today.